In two ongoing studies NCT03595540 and NCT03340935 testing the safety and feasibility of FMD in cancer patients in conjunction with any type of anti-cancer therapy, a total of 12 patients with metastatic hormone receptor-positive breast cancer have been included (5 in NCT03595540, 7 in NCT03340935). This evidence concerns the gene NR4A1 and cancer.